HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 8, 2009, Pages 1331-1337

  Valenti, Luca ^a   Girelli, Domenico ^b   Valenti, Giovanni Francesco ^c   Castagna, Annalisa ^b   Como, Giovanna ^c   Campostrini, Natascia ^b   Rametta, Raffaela ^a   Dongiovanni, Paola ^a   Messa, Piergiorgio ^c   Fargion, Silvia ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FERRIC GLUCONATE; FERRITIN; HEPCIDIN; HEPCIDIN 25; HFE PROTEIN; IRON; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; ANTIMICROBIAL CATIONIC PEPTIDE; BIOLOGICAL MARKER; HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; MEMBRANE PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; IRON BLOOD LEVEL; IRON STORAGE; MAJOR CLINICAL STUDY; MALE; QUANTITATIVE ANALYSIS; RESTRICTION MAPPING; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; BLOOD; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; ERYTHROPOIESIS; GENETICS; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; MUTATION; RENAL REPLACEMENT THERAPY;

ADULT; AGED; ANEMIA; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; ERYTHROPOIESIS; FEMALE; FERRITINS; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INFLAMMATION; IRON; KIDNEY FAILURE, CHRONIC; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; RENAL DIALYSIS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; YOUNG ADULT;

EID: 70349925449     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01370209     Document Type: Article

References (36)

1. Kato A, Tsuji T, Luo J, Sakao Y, Yasuda H, Hishida A: Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol 28: 115-121, 2008
2. Kulaksiz H, Gehrke SG, Janetzko A, Rost D, Bruckner T, Kallinowski B, Stremmel W: Pro-hepcidin: Expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut 53: 735-743, 2004
3. Malyszko J, Mysliwiec M: Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res 30: 15-30, 2007
4. Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, Ishikawa I: Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 108: 1381-1387, 2006
5. Kemna EH, Tjalsma H, Willems HL, Swinkels DW: Hepcidin: From discovery to differential diagnosis. Haematologica 93: 90-97, 2008
6. Paganini EP: Overview of anemia associated with chronic renal disease: Primary and secondary mechanisms. Semin Nephrol 9: 3-8, 1989
7. Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, Greenwood R, Feldman HI, Port FK, Held PJ: Anaemia in haemodialysis patients of five European countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19: 121-132, 2004
8. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougal IC, Macleod A, Wiecek A, Cameron, S: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19 [Suppl 2]: ii1- 47, 2004
9. Strippoli GF, Tognoni G, Navaneethan SD, Nicolucci A, Craig JC: Haemoglobin targets: We were wrong, time to move on. Lancet 369: 346-350, 2007
10. Miyashita K, Tojo A, Kimura K, Goto A, Omata M, Nishiyama K, Fujita T: Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients. Hypertens Res 27: 79-84, 2004
11. Phrommintikul A, Haas SJ, Elsik M, Krum H: Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet 369: 381-388, 2007
12. Valenti L, Valenti G, Como G, Burdick L, Santorelli G, Dongiovanni P, Rametta R, Bamonti F, Novembrino C, Fracanzani AL, Messa PG, Fargion S: HFE gene mutations and oxidative stress influence serum ferritin, associated with vascular damage, in hemodialysis patients. Am J Nephrol 27: 101-107, 2007
13. Seifert A, von Herrath D, Schaefer K: Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. Q J Med 65: 1015-1024, 1987
14. Jean G, Charra B, Chazot C, Vanel T, Terrat JC, Hurot JM, Laurent G: Risk factor analysis for long-term tunneled dialysis catheter-related bacteremias. Nephron 91: 399-405, 2002
15. Teehan GS, Bahdouch D, Ruthazer R, Balakrishnan VS, Snydman DR, Jaber BL: Iron storage indices: Novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis 38: 1090-1094, 2004
16. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG: Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16: 3070-3080, 2005
17. Stenvinkel P: Anaemia and inflammation: What are the implications for the nephrologist? Nephrol Dial Transplant 18 [Suppl 8]: viii17-22, 2003
18. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Liu E, Kopple JD: A low serum iron level is a predictor of poor outcome in hemodialysis patients. Am J Kidney Dis 43: 671-684, 2004
19. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH: Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 19: 141-149, 2004
20. Torti FM, Torti SV: Regulation of ferritin genes and protein. Blood 99: 3505-3516, 2002
21. Scaccabarozzi A, Arosio P, Weiss G, Valenti L, Dongiovanni P, Fracanzani AL, Mattioli M, Levi S, Fiorelli G, Fargion S: Relationship between TNF-alpha and iron metabolism in differentiating human monocytic THP-1 cells. Br J Haematol 110: 978-984, 2000
22. Rocha LA, Barreto DV, Barreto FC, Dias CB, Moyses R, Silva MR, Moura LA, Draibe SA, Jorgetti V, Carvalho AB, Canziani ME: Serum ferritin level remains a reliable marker of bone marrow iron stores evaluated by histomorphometry in hemodialysis patients. Clin J Am Soc Nephrol 4: 105-109, 2009
23. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, Dawkins FW, Acton RT, Harris EL, Gordeuk VR, Leiendecker-Foster C, Speechley M, Snively BM, Holup JL, Thomson E, Sholinsky P: Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 352: 1769-1778, 2005
24. Pietrangelo A: Hemochromatosis: An endocrine liver disease. Hepatology 46: 1291-1301, 2007
25. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, Nizet V, Johnson RS: Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 117: 1926-1932, 2007
26. Pinto JP, Ribeiro S, Pontes H, Thowfeequ S, Tosh D, Carvalho F, Porto G: Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha. Blood 111: 5727-5733, 2008
27. Swinkels DW, Girelli D, Laarakkers C, Kroot J, Campostrini N, Kemna EH, Tjalsma H: Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS ONE 3: e2706, 2008
28. Camaschella C: Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood 106: 3710-3717, 2005
29. Vujic Spasic M, Kiss J, Herrmann T, Galy B, Martinache S, Stolte J, Grone HJ, Stremmel W, Hentze MW, Muckenthaler MU: Hfe acts in hepatocytes to prevent hemochromatosis. Cell Metab 7: 173-178, 2008
30. Piperno A, Girelli D, Nemeth E, Trombini P, Bozzini C, Poggiali E, Phung Y, Ganz T, Camaschella C: Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. Blood 110: 4096-4100, 2007
31. Valenti L, Valenti G, Como G, Santorelli G, Dongiovanni P, Rametta R, Fracanzani AL, Tavazzi D, Messa PG, Fargion S: HFE Genotype influences erythropoiesis support requirement in hemodialysis patients: A prospective study. Am J Nephrol 28: 311-316, 2008
32. Valenti L, Conte D, Piperno A, Dongiovanni P, Fracanzani AL, Fraquelli M, Vergani A, Gianni C, Carmagnola L, Fargion S: The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis. J Med Genet 41: 946-950, 2004
33. Bozzini C, Campostrini N, Trombini P, Nemeth E, Castagna A, Tenuti I, Corrocher R, Camaschella C, Ganz T, Olivieri O, Piperno A, Girelli D: Measurement of urinary hepcidin levels by SELDI-TOF-MS in HFE-hemochromatosis. Blood Cells Mol Dis 40: 347-352, 2008
34. Nemeth E, Roetto A, Garozzo G, Ganz T, Camaschella C: Hepcidin is decreased in TFR2 hemochromatosis. Blood 105: 1803-1806, 2005
35. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M: Immunoassay for human serum hepcidin. Blood 112: 4292-4297, 2008
36. Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY: Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 117: 1933-1939, 2007